Login / Signup

Readily available biomarkers predict poor survival in metastatic pancreatic cancer.

Marin StrijkerEran van VeldhuisenLydia G M van der GeestOlivier R BuschMaarten F BijlsmaNadia Haj MohammadMarjolein Y HomsJeanin E van HooftJoanne VerheijJudith De Vos-GeelenJohanna W WilminkW Ewout W SteyerbergMarc G H BesselinkHanneke Wilma Marlies van Laarhovennull null
Published in: Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals (2021)
In mPC patients, albumin, CA19-9, CRP, LDH, CRP/albumin ratio, and (m)GPS are prognostic for poor survival. Biomarkers did not predict response to chemotherapy. These readily available biomarkers can be used to better inform patients and to stratify in clinical trials.
Keyphrases
  • end stage renal disease
  • clinical trial
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • squamous cell carcinoma
  • peritoneal dialysis
  • patient reported outcomes
  • radiation therapy